Comprehensive Stock Comparison
Compare PMGC Holdings Inc. (ELAB) vs Eli Lilly and Company (LLY) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth |  ELAB | 44.1% revenue growth vs LLY's 32.0% |
| Quality / Margins |  LLY | 31.0% net margin vs ELAB's -253.1% |
| Stability / Safety | LLY | Beta 0.65 vs ELAB's 1.74 |
| Dividends | LLY | 0.5% yield; 10-year raise streak; ELAB pays no meaningful dividend |
| Momentum (1Y) | LLY | +8.6% vs ELAB's -96.5% |
| Efficiency (ROA) | LLY | 16.0% ROA vs ELAB's -44.6%, ROIC 33.7% vs -82.7% |
Who Each Stock Is For
Income & stability
LLYDividend streak 10 yrs, beta 0.65, yield 0.5%
Growth exposure
ELABRev growth 44.1%, EPS growth 86.0%, 3Y rev CAGR 13.4%
Long-term compounding (10Y)
LLY13.2% 10Y total return vs ELAB's -100.0%
Sleep-well-at-night portfolio
LLYLower volatility, beta 0.65, current ratio 1.15x
Defensive / Recession hedge
LLYBeta 0.65, yield 0.5%, current ratio 1.15x
Business Model
What each company does and how it makes money
PMGC Holdings is a biopharmaceutical company developing novel aesthetic medicines and therapeutic products, with a focus on engineered probiotics for muscle preservation during weight loss treatments. It generates revenue primarily through research and development activities, investment operations, and potential future commercialization of its lead product EL-22 — a first-in-class probiotic targeting obesity-related muscle loss. The company's competitive advantage lies in its proprietary engineered probiotic technology platform addressing an emerging need in the rapidly growing GLP-1 weight loss market.
Eli Lilly is a global pharmaceutical company that discovers, develops, and markets innovative medicines for serious diseases like diabetes, cancer, and autoimmune disorders. It generates revenue primarily from drug sales — with diabetes treatments like Trulicity and Mounjaro contributing over 50% of revenue — and from oncology and immunology products. The company's competitive advantage lies in its deep research and development capabilities, particularly in diabetes and obesity treatments where it has established a strong patent-protected portfolio.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
LLY 4ELAB 1LLY6/6 metricsELAB3/3 metricsLLY6/8 metricsLLY6/6 metricsLLY2/2 metricsLLY leads in 4 of 6 categories (Financial Metrics, Profitability & Efficiency). ELAB leads in 1 (Valuation Metrics).
Financial Metrics (TTM)
LLY and ELAB operate at a comparable scale, with $59.4B and -$1M in trailing revenue. LLY is the more profitable business, keeping 31.0% of every revenue dollar as net income compared to ELAB's -2.5%. On growth, LLY holds the edge at +53.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ELABPMGC Holdings Inc. | LLYEli Lilly and Com… |
|---|---|---|
| RevenueTrailing 12 months | -$1M | $59.4B |
| EBITDAEarnings before interest/tax | -$4M | $28.6B |
| Net IncomeAfter-tax profit | -$7M | $18.4B |
| Free Cash FlowCash after capex | -$7M | $9.0B |
| Gross MarginGross profit ÷ Revenue | +72.8% | +83.0% |
| Operating MarginEBIT ÷ Revenue | -75.7% | +45.0% |
| Net MarginNet income ÷ Revenue | -2.5% | +31.0% |
| FCF MarginFCF ÷ Revenue | -2.2% | +15.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | -45.8% | +53.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +100.0% | +4.8% |
Valuation Metrics
| Metric | ELABPMGC Holdings Inc. | LLYEli Lilly and Com… |
|---|---|---|
| Market CapShares × price | $23,875 | $898.2B |
| Enterprise ValueMkt cap + debt − cash | -$4M | $928.6B |
| Trailing P/EPrice ÷ TTM EPS | -0.00x | 85.70x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 29.43x |
| PEG RatioP/E ÷ EPS growth rate | — | 13.94x |
| EV / EBITDAEnterprise value multiple | — | 48.19x |
| Price / SalesMarket cap ÷ Revenue | 0.01x | 19.94x |
| Price / BookPrice ÷ Book value/share | 0.00x | 63.57x |
| Price / FCFMarket cap ÷ FCF | — | 2168.03x |
Profitability & Efficiency
LLY delivers a 77.2% return on equity — every $100 of shareholder capital generates $77 in annual profit, vs $-78 for ELAB. On the Piotroski fundamental quality scale (0–9), LLY scores 6/9 vs ELAB's 4/9, reflecting solid financial health.
| Metric | ELABPMGC Holdings Inc. | LLYEli Lilly and Com… |
|---|---|---|
| ROE (TTM)Return on equity | -78.4% | +77.2% |
| ROA (TTM)Return on assets | -44.6% | +16.0% |
| ROICReturn on invested capital | -82.7% | +33.7% |
| ROCEReturn on capital employed | -33.7% | +40.2% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 6 |
| Debt / EquityFinancial leverage | — | 2.36x |
| Net DebtTotal debt minus cash | -$4M | $30.4B |
| Cash & Equiv.Liquid assets | $4M | $3.3B |
| Total DebtShort + long-term debt | $0 | $33.6B |
| Interest CoverageEBIT ÷ Interest expense | -17.68x | 26.09x |
Total Returns (with DRIP)
A $10,000 investment in LLY five years ago would be worth $49,693 today (with dividends reinvested), compared to $1 for ELAB. Over the past 12 months, LLY leads with a +8.6% total return vs ELAB's -96.5%. The 3-year compound annual growth rate (CAGR) favors LLY at 47.3% vs ELAB's -96.0% — a key indicator of consistent wealth creation.
| Metric | ELABPMGC Holdings Inc. | LLYEli Lilly and Com… |
|---|---|---|
| YTD ReturnYear-to-date | -26.1% | -6.9% |
| 1-Year ReturnPast 12 months | -96.5% | +8.6% |
| 3-Year ReturnCumulative with dividends | -100.0% | +219.8% |
| 5-Year ReturnCumulative with dividends | -100.0% | +396.9% |
| 10-Year ReturnCumulative with dividends | -100.0% | +1316.4% |
| CAGR (3Y)Annualised 3-year return | -96.0% | +47.3% |
Risk & Volatility
LLY is the less volatile stock with a 0.65 beta — it tends to amplify market swings less than ELAB's 1.74 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LLY currently trades 88.5% from its 52-week high vs ELAB's 3.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ELABPMGC Holdings Inc. | LLYEli Lilly and Com… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.74x | 0.65x |
| 52-Week HighHighest price in past year | $30.50 | $1133.95 |
| 52-Week LowLowest price in past year | $1.01 | $623.78 |
| % of 52W HighCurrent price vs 52-week peak | +3.4% | +88.5% |
| RSI (14)Momentum oscillator 0–100 | 16.2 | 44.8 |
| Avg Volume (50D)Average daily shares traded | 1.6M | 3.0M |
Analyst Outlook
LLY is the only dividend payer here at 0.52% yield — a key consideration for income-focused portfolios.
| Metric | ELABPMGC Holdings Inc. | LLYEli Lilly and Com… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $1214.28 |
| # AnalystsCovering analysts | — | 44 |
| Dividend YieldAnnual dividend ÷ price | — | +0.5% |
| Dividend StreakConsecutive years of raises | — | 10 |
| Dividend / ShareAnnual DPS | — | $5.18 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.3% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Nov 23 | Mar 26 | Change |
|---|---|---|---|
| PMGC Holdings Inc. (ELAB) | 100 | 0.01 | -100.0% |
| Eli Lilly and Compa… (LLY) | 100 | 174.3 | +74.3% |
Eli Lilly and Compa… (LLY) returned +397% over 5 years vs PMGC Holdings Inc. (ELAB)'s -100%. A $10,000 investment in LLY 5 years ago would be worth $49,693 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| PMGC Holdings Inc. (ELAB) | $0.00 | $2M | — |
| Eli Lilly and Compa… (LLY) | $20.0B | $45.0B | +125.7% |
Eli Lilly and Company's revenue grew from $20.0B (2015) to $45.0B (2024) — a 9.5% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| PMGC Holdings Inc. (ELAB) | -948.9% | -2.5% | +99.7% |
| Eli Lilly and Compa… (LLY) | 12.1% | 23.5% | +94.8% |
Eli Lilly and Company's net margin went from 12% (2015) to 24% (2024).
Chart 4P/E Ratio History — 7 Years
| Stock | 2018 | 2024 | Change |
|---|---|---|---|
| Eli Lilly and Compa… (LLY) | 37 | 65.9 | +78.1% |
Eli Lilly and Company has traded in a 15x–101x P/E range over 7 years; current trailing P/E is ~86x.
Chart 5EPS Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| PMGC Holdings Inc. (ELAB) | -0.08 | -274.68 | -332442.4% |
| Eli Lilly and Compa… (LLY) | 2.18 | 11.71 | +437.2% |
Eli Lilly and Company's EPS grew from $2.18 (2015) to $11.71 (2024) — a 21% CAGR.
Chart 6Free Cash Flow — 5 Years
PMGC Holdings Inc. generated $-5M FCF in 2024 (-691% vs 2021). Eli Lilly and Company generated $414M FCF in 2024 (-92% vs 2021).
ELAB vs LLY: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is ELAB or LLY a better buy right now?
Eli Lilly and Company (LLY) offers the better valuation at 85.7x trailing P/E (29.4x forward), making it the more compelling value choice. Analysts rate Eli Lilly and Company (LLY) a "Buy" — based on 44 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ELAB or LLY?
Over the past 5 years, Eli Lilly and Company (LLY) delivered a total return of +396.9%, compared to -100.0% for PMGC Holdings Inc. (ELAB). A $10,000 investment in LLY five years ago would be worth approximately $50K today (assuming dividends reinvested). Over 10 years, the gap is even starker: LLY returned +1316% versus ELAB's -100.0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ELAB or LLY?
By beta (market sensitivity over 5 years), Eli Lilly and Company (LLY) is the lower-risk stock at 0.65β versus PMGC Holdings Inc.'s 1.74β — meaning ELAB is approximately 167% more volatile than LLY relative to the S&P 500.
04Which has better profit margins — ELAB or LLY?
Eli Lilly and Company (LLY) is the more profitable company, earning 23.5% net margin versus -253.1% for PMGC Holdings Inc. — meaning it keeps 23.5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LLY leads at 38.9% versus -75.7% for ELAB. At the gross margin level — before operating expenses — LLY leads at 81.3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — ELAB or LLY?
In this comparison, LLY (0.5% yield) pays a dividend. ELAB does not pay a meaningful dividend and should not be held primarily for income.
06Is ELAB or LLY better for a retirement portfolio?
For long-horizon retirement investors, Eli Lilly and Company (LLY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.65), 0.5% yield, +1316% 10Y return). PMGC Holdings Inc. (ELAB) carries a higher beta of 1.74 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LLY: +1316%, ELAB: -100.0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between ELAB and LLY?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. LLY pays a dividend while ELAB does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.